+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study



Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study



Current Medical Research and Opinion 24(9): 2467-2476



Poor results from lipid-lowering therapy are mainly due to inadequate dosing and increased adverse effects with high-dose statin monotherapy or drug combinations. The SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) study evaluated the effectiveness of either ezetimibe (EZE) 10 mg as monotherapy or co-administered with on-going statin treatment (S + EZE) in clinical practice. A total of 1053 dyslipidaemic patients (52% men, age 60.3 years, 42.9% with CHD, 32.0% with diabetes mellitus and 69.6% with hypertension) were enrolled. The majority (n=986; 93.6%) were treated with EZE as 'add-on' to their already prescribed statin, the rest only received EZE (n=67). Baseline lipid levels were compared with those obtained 16 weeks after initiating treatment. Total (TC) and low density lipoprotein cholesterol (LDL-C), as well as triglycerides (TG) decreased significantly with S + EZE (by 25.3%, 31.4% and 28.9%, respectively; p<0.0001 for all comparisons), while monotherapy with EZE resulted in a decrease of 20.8% for TC (p<0.0001), 28.0% for LDL-C (p<0.0001) and 28.8% for TG (p=0.016). At the end of the study 43.9% of patients achieved target TC (<5.0 mmol/L for primary prevention and <4.5 mmol/L for secondary prevention), 50.5% target LDL-C (<3.0 mmol/L for primary prevention and <2.5 mmol/L for secondary prevention) and 61.6% target TG (<2.0 mmol/L). The overall incidence of adverse effects during the treatment period, and probably related to EZE use, was low (n=6, 0.6% of patients). (1) S + EZE combination therapy was effective and safe irrespective of the statin used, (2) the S + EZE combination resulted in significantly more patients reaching their recommended target lipid levels and (3) the lipid-lowering efficacy of EZE in monotherapy as well as of the S + EZE combination was related to initial lipid values. The much greater decrease of TG than expected could be, at least in part, due to better control/compliance regarding diet and drug treatment during the study and adherence to the need for an overnight fast before sampling.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911135

Download citation: RISBibTeXText

PMID: 18655751

DOI: 10.1185/03007990802303772


Related references

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 223(2): 251-261, 2013

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clinic Proceedings 80(5): 587-595, 2005

Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. Current Medical Research and Opinion 2016: 1-6, 2016

Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. Mayo Clinic Proceedings 81(9): 1177-1185, 2006

RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. Lipids in Health and Disease 12: 142, 2014

Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-. Circulation Journal 75(10): 2496-2504, 2012

Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Current Medical Research and Opinion 24(1): 249-259, 2007

Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. Journal of Cardiovascular Pharmacology and Therapeutics 13(1): 72-79, 2008

Changes of plaque composition and morphology after treatment with statin only or statin plus ezetimibe assessed by dual source CT Computed Tomography. European Heart Journal 34(Suppl 1): P4688-P4688, 2013

Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy. Clinical Drug Investigation 27(5): 333-337, 2007

Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. American Journal of Cardiology 103(3): 369-374, 2009

Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis. International Journal of Cardiology 225: 50-59, 2016

Addition of ezetimibe to ongoing statin therapy Incremental reduction in low-density lipoprotein cholesterol is independent of statin type. European Heart Journal 23(Abstract Supplement): 19, August-September, 2002

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes, Obesity and Metabolism 13(7): 615-628, 2011

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. Journal of Clinical Lipidology 10(3): 556-567, 2017